ADVOCACY

EAACI seeks to tackle the burden of allergy in Europe with evidence-based recommendations and by joining forces with relevant European actors in the field.

To find out  about our initiatives at the EU level, upcoming events and campaigns :

	European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) to advocate better patient care
	European Chronic Disease Alliance (ECDA) to raise awareness among policy makers about the surge in chronic diseases
	Alliance for Biomedical Research in Europe (BioMed Alliance) to promote excellence and innovation in European biomedical research
	European Medicines Agency (EMA) to support safe and effective quality interventions for allergic diseases and asthma

The European Strategic Forum on Allergic Diseases

The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision‐makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real‐world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.

Read the full manuscript here.